BodyLogicMD places hormone assessment and testing prominently in its menopause offering. A reader may therefore arrive expecting a test to explain every part of a treatment plan. The more useful question is what clinical purpose a proposed medicine serves and which parts of the history a laboratory result cannot supply.

We examined the network’s menopause, clinician-access and pricing pages on September 29, 2026. They establish a relevant care service, but not a verified progesterone catalog or a personal treatment recommendation. This review considers how the public offer relates to the uterus question without claiming that BodyLogicMD follows an intake or monitoring protocol that its pages do not document.

Editorial illustration: two consultation chairs and a notebook on a side table.
BodyLogicMD menopause review: what testing can leave unanswered about progesterone — bring the unanswered questions into the appropriate professional conversation.

Start with the reason for seeking care

The menopause page discusses symptoms and hormone treatment through the BodyLogicMD network. Its promotional account of improvement is not evidence that every symptom has a hormonal cause or that every proposed medicine addresses the same concern. In a consultation, the requested outcome should be expressed plainly enough to revisit later: what is being treated, and what would count as a useful response? Defy Medical also advertises individualized hormone care, but that shared description does not make the services or their future prescriptions equivalent. Both leave a reader needing an explanation tied to the actual clinical assessment. A clear starting explanation would also separate what the patient hopes will improve from what the clinician is trying to prevent. Those aims can coexist, but they need different explanations and should not disappear into a single before-and-after description of hormone balance.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
Start with the reason for seeking care — keep the exact product identity and its complete label together.

A laboratory result cannot supply the surgical record

BodyLogicMD describes testing as part of its assessment approach. That does not show which tests a particular clinician would request, why, or how prior surgery would be considered. ACOG’s hysterectomy information distinguishes removal of the uterus, retention of the cervix in a supracervical procedure, and separate removal of ovaries. Those are historical facts to clarify with the treating professional, not conclusions to draw from a hormone number. The hysterectomy questions guide helps frame that discussion. A report marked within range would not, by itself, document the reason for including or omitting a medicine.

Endometrial protection is a particular objective

The British Menopause Society’s clinical tool discusses progestogens specifically in relation to protection of the uterine lining during relevant estrogen treatment. That is a narrower objective than a general promise to optimize hormone balance. It also depends on the preparation and treatment context; this review provides no schedule or quantity to apply independently. A BodyLogicMD clinician’s explanation should make clear whether that objective is relevant to the proposed plan and what supports the selected approach. Our systemic estrogen discussion separates this purpose from the symptom that originally prompted the visit. The network page does not document an individual answer.

Editorial illustration: an open reference book, a magnifying glass and a document.
Endometrial protection is a particular objective — follow the source behind a claim as well as the advertised description.

Local symptoms need their own treatment context

The NAMS 2020 genitourinary consensus abstract treats low-dose vaginal estrogen differently from general systemic-treatment assumptions: it says a progestogen is not indicated with that therapy, but reports no endometrial-safety clinical trials beyond one year. That limitation belongs with the statement. Neither the word vaginal nor the name estrogen on an incomplete medicine list establishes that a particular product falls within the statement’s scope. The local estrogen guide explains why exact identity matters. BodyLogicMD’s clinician directory identifies a network, not which local or systemic formulation an individual clinician would recommend or supply.

Membership buys access to pricing, not every treatment

The published pricing page describes BodyLogicMD Advantage at $79 per month, on a month-to-month basis with cancellation available. Testing and treatment are offered at member pricing; they are not all included in that membership amount. The figure consequently cannot be treated as the total cost of progesterone care or as the price of a comprehensive reassessment. Ask for the selected clinician’s charges and what further visits or investigations would cost. Renew Youth uses a different entry offer, illustrating why an advertised starting amount is a poor substitute for a written account of the care actually proposed.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
Membership buys access to pricing, not every treatment — keep the exact product identity and its complete label together.

Changed symptoms should not be reduced to a score

A follow-up needs room for information that does not fit a before-and-after hormone comparison. NHS guidance on postmenopausal bleeding says it should be checked even after a single small episode. It also explains that bleeding is not usually serious but can sometimes indicate cancer. Those points support contacting a professional, not assigning a cause or changing hormones through this review. The bleeding and hormone-plan guide keeps assessment separate from product selection. BodyLogicMD’s general care description does not establish a particular clinician’s urgent-contact arrangements, investigation pathway or coordination with an existing gynecologist.

Compare the clinician’s explanation as well as the network

The network directory is a starting point for identifying care, not proof of a current appointment or a personal match. Before treating a test-led offer as complete, unresolved questions include who interprets the history, who explains the selected medicine’s purpose, and who reviews a change in symptoms. A named clinic’s answers may be more useful than network-wide marketing language. The care comparison places different delivery models alongside one another without ranking medical quality. For BodyLogicMD, the strongest documented conclusion is that a menopause service exists; the merits and content of a specific treatment plan still require an accountable clinical conversation.

Sources behind this article

Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.

  1. BodyLogicMD: MenopauseProvider menopause service and attributed testing or outcome claims; not comparative clinical evidence · Checked 2026-09-29
  2. ACOG: HysterectomyUS professional patient guidance, updated September 2024 and reviewed May 2025; distinguishes operative terms without inferring an individual operation or hormone need · Checked 2026-09-29
  3. British Menopause Society: Progestogens and endometrial protectionUK professional clinical tool, internally reviewed February 2026; May 2026 is the URL/file version, not the stated review month. Preparation-specific evidence and endometrial-protection limits, with no dose or schedule instructions reproduced · Checked 2026-09-29
  4. NAMS: The 2020 genitourinary syndrome of menopause position statement — abstractPublished professional consensus abstract only; low-dose vaginal estrogen distinction retains absent endometrial-safety clinical trials beyond one year, not a complete-paper or individualized assessment · Checked 2026-09-29
  5. BodyLogicMD: Find a bioidentical hormone doctorProvider network and access description; no individual provider availability or exact capsule confirmed · Checked 2026-09-29
  6. BodyLogicMD: PricingProvider membership and member-pricing terms; membership does not include every test or treatment · Checked 2026-09-29
  7. NHS: Postmenopausal bleedingUK public patient guidance, reviewed September 24, 2026; bleeding assessment advice does not diagnose a cause or transfer NHS referral timings to US services · Checked 2026-09-29
Read our editorial method →